Jushakar Sucralfate Cefidizime may decrease the excretion rate of Sucralfate which could result in a higher serum level. Hydralazine Cefotaxime may decrease the excretion rate of Hydralazine which could result in a higher serum level. The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins PBPs. Technetium Tcm disofenin Cefotaxime may decrease the excretion rate of Technetium Tcm disofenin which could result in a higher serum level. Amikacin The risk or severity zodium nephrotoxicity can be increased when Amikacin is combined with Cefotaxime.
|Published (Last):||12 July 2006|
|PDF File Size:||20.72 Mb|
|ePub File Size:||4.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
Certain immunomodulatory properties of the drug might account for its increased in vivo activity against specific bacterial species. These immunomodulatory properties stimulate some phagocyte and lymphocyte cellular functions when they have been impaired.
In vitro susceptible gram positive bacteria include: methicillin-sensitive Staphylococcus aureus , and Streptococcus agalactiae , S. Cefodizime was shown to be ineffective in vitro against Enterobacter spp. Gram positive bacteria it was inactive against include Staphylococcus epidermidis and methicillin-resistant Streptococcus aureus.
The drug reaches minimum inhibitory concentrations approximately 2—3 hours after administration, maintaining it for several hours afterwards. Clearance of cefodizime from the body is predominantly renal, with the majority of the drug excreted unchanged within the first 12 hours. More specifically, cefodizime is mainly cleared via glomerular filtration in the kidney, in addition to some tubular secretion. In patients with normal renal function, the terminal phase elimination half-life is approximately 3.
Gastrointestinal adverse effects were observed in 2. Allergic symptoms were observed in 1. Other adverse effects observed include local site reactions, pain at site of injection, and phlebitis. In clinical trials, the most frequently used adult dosages ranged from 2 grams to 4 grams IM or IV per day given as a single dose or in 2 divided doses.